DiaMedica Therapeutics Inc. Stock Toronto S.E.
Stocks
DMA
CA25253X2077
Biotechnology & Medical Research
| Market Cap | 425M 304M 263M 242M 227M 28.94B 432M 2.86B 1.12B 14.08B 1.14B 1.12B 48.77B | P/E Ratio 2026 * |
-6.81x | P/E Ratio 2027 * | -6.42x |
|---|---|---|---|---|---|
| Enterprise Value | 425M 304M 263M 242M 227M 28.94B 432M 2.86B 1.12B 14.08B 1.14B 1.12B 48.77B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
56.7% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: DiaMedica Therapeutics Inc.
| 1 day | -2.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 54 | 01/01/2010 |
Scott Kellen
DFI | Director of Finance/CFO | 60 | 01/04/2018 |
Julie Krop
CTO | Chief Tech/Sci/R&D Officer | 60 | 11/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Giuffre
BRD | Director/Board Member | 70 | 10/08/2010 |
Rick Pauls
CHM | Chairman | 54 | 01/04/2008 |
James Parsons
CHM | Chairman | 60 | 01/01/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.11% | -5.12% | - | - | 304M | |
| -2.86% | -0.26% | +57.57% | +110.98% | 56.42B | |
| -0.34% | +2.91% | +45.55% | +46.87% | 44.54B | |
| +1.26% | +7.35% | -13.68% | -18.78% | 22.9B | |
| +1.16% | +5.21% | -2.47% | +395.15% | 21.21B | |
| -0.51% | -5.56% | +10.43% | -29.97% | 16.4B | |
| -1.54% | -1.06% | +8.10% | -39.28% | 15.4B | |
| -0.51% | +2.05% | +26.47% | +176.44% | 13.35B | |
| +0.96% | +6.56% | +20.81% | - | 12.36B | |
| +0.32% | +1.60% | +96.37% | +207.56% | 11.15B | |
| Average | -0.43% | +1.66% | +27.68% | +106.12% | 23.75B | |
| Weighted average by Cap. | -0.70% | +2.54% | +32.25% | +98.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -63.21M -45.27M -39.1M -36.03M -33.73M -4.3B -64.19M -425M -166M -2.09B -170M -166M -7.25B | -78.02M -55.88M -48.27M -44.48M -41.63M -5.31B -79.23M -525M -205M -2.59B -210M -205M -8.95B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
